Editor’s note: Discover the current COVID-19 news and assistance in Medscape’s Coronavirus Resource Center
2 COVID-19 antibody treatments, one developed by Regeneron and the other by Eli Lilly, show guarantee in the outpatient setting in outcomes launched on Wednesday.
Regeneron, in a randomized, double-blind trial, is assessing the effect of including its investigational antibody mixed drink REGN-COV2 to normal standard of care in comparison with adding placebo to requirement of care. The data described Wednesday, which involve an extra 524 patients, show that the trial met all of the very first 9 endpoints.
Regeneron revealed prospective results from its phase 2/3 trial revealing REGN-COV2 substantially reduced viral load and client medical check outs, that included hospitalizations, check outs to an emergency situation department, visits for immediate care, and/or doctor office/telemedicine sees.
Interest in the cocktail surged after President Donald Trump proclaimed its benefits after it was utilized in his own COVID-19 treatment previously this month.
Trump got the greatest dose of the drug, 8 g, however, according to a Regeneron press release announcing the current findings, “results revealed no significant difference in virologic or medical effectiveness in between the REGN-COV2 high dosage (8 grams) and low dosage (2.4 grams).”
The company explained additional outcomes of the industry-funded study in the release: “On the primary endpoint, the typical everyday modification in viral load through day 7 (suggest time-weighted average c